Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lizza E L Hendriks

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLCJordi Remon, Lizza E L Hendriks
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
The Lancet. Respiratory Medicine|October 1, 2025
Rethinking immunotherapy in patients with SCLC with poor performance statusNoemi Reguart, Lizza E L Hendriks
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2023
Speeding up Antibody-Drug Conjugate Development in Pretreated <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerLizza E L Hendriks, Jordi Remon
Translational Lung Cancer Research|July 18, 2020
First-line immune-chemotherapy combination for squamous NSCLC is already a realityLizza E L Hendriks, Jessica Menis, Jordi Remon
Expert Opinion on Investigational Drugs|March 10, 2017
Heat shock protein antagonists in early stage clinical trials for NSCLCLizza E L Hendriks, Anne-Marie C Dingemans
Lung Cancer (Amsterdam, Netherlands)|February 11, 2019
Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?Lizza E L Hendriks, Anne-Marie C Dingemans
Clinical Lung Cancer|July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 ExpressionLizza E L Hendriks, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2021
Paving the Way for Long-Term Survival in Non-Small-Cell Lung CancerJordi Remon, Lizza E L Hendriks, Benjamin Besse
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 1, 2021
Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLCJordi Remon, Lizza E L Hendriks
Mediastinum (Hong Kong, China)|February 4, 2022
Targeted therapies for unresectable stage III non-small cell lung cancerJordi Remon, Lizza E L Hendriks
The Lancet. Respiratory Medicine|October 1, 2025
Rethinking immunotherapy in patients with SCLC with poor performance statusNoemi Reguart, Lizza E L Hendriks
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 12, 2023
Speeding up Antibody-Drug Conjugate Development in Pretreated <i>EGFR</i>-Mutant Non-Small-Cell Lung CancerLizza E L Hendriks, Jordi Remon
Translational Lung Cancer Research|July 18, 2020
First-line immune-chemotherapy combination for squamous NSCLC is already a realityLizza E L Hendriks, Jessica Menis, Jordi Remon
Expert Opinion on Investigational Drugs|March 10, 2017
Heat shock protein antagonists in early stage clinical trials for NSCLCLizza E L Hendriks, Anne-Marie C Dingemans
Lung Cancer (Amsterdam, Netherlands)|February 11, 2019
Is it time to incorporate surgery in the treatment of stage IV non-small cell lung cancer?Lizza E L Hendriks, Anne-Marie C Dingemans
Clinical Lung Cancer|July 19, 2021
Dorian Gray Syndrome of Upfront Immunotherapy in Patients With Non-Small-Cell Lung Cancer and High PD-L1 ExpressionLizza E L Hendriks, Jordi Remon, Benjamin Besse
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
The POSEIDON Trial: Will Secondary End Points Change Our Clinical Practice?Jordi Remon, Lizza E L Hendriks, Martin Reck
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 8, 2021
Paving the Way for Long-Term Survival in Non-Small-Cell Lung CancerJordi Remon, Lizza E L Hendriks, Benjamin Besse
Pageof 18